Healy David
Cardiff University, Department of Psychological Medicine, Hergest Unit, Ysbyty Gwynedd, Bangor, Wales, UK.
Transcult Psychiatry. 2009 Mar;46(1):16-37. doi: 10.1177/1363461509102285.
This article considers the dominance that randomized controlled trials (RCTs) of psychotropic agents currently have in relation to the practice of psychiatry in mental health and primary care settings. In contemporary psychiatry, data of marginal significance based on rating scale measures are privileged as evidence that treatments are effective, while judgments of drug effects based on clinical practice are downgraded. The dominance of RCTs has also led to an increasing promotion of rating scales in clinical practice, described here as ;rating scale mongering.' The logical consequence of current interpretations of RCT data is that clinicians should adhere to guidelines which are based on a systematic assembly of such data, but the selective publication of trial data and ghostwriting of publications, lays the basis for guideline capture, and a corresponding capture of evidence-based clinical practice by pharmaceutical companies.
本文探讨了精神药物随机对照试验(RCTs)目前在心理健康和初级保健环境中的精神病学实践中所占据的主导地位。在当代精神病学中,基于评定量表测量的意义不大的数据被视为治疗有效的证据,而基于临床实践的药物疗效判断则被贬低。RCTs的主导地位还导致评定量表在临床实践中的推广日益增加,这里将其描述为“评定量表兜售”。当前对RCT数据的解释所产生的逻辑后果是,临床医生应遵循基于此类数据系统汇总的指南,但试验数据的选择性发表和出版物的代笔行为,为制药公司进行指南俘获以及相应地俘获循证临床实践奠定了基础。